Sponsor:
Donald Gilbert, MD, MS, FAAN, FAAP
Code:
NCT04421248
Conditions
Attention Deficit Hyperactivity Disorder Combined
Eligibility Criteria
Sex: All
Age: 8 - 12
Healthy Volunteers: Accepted
Interventions
Methylphenidate
Placebo
Brief summary:
Conditions
Attention Deficit Hyperactivity Disorder Combined
Study ID
NCT04421248
Start date
Sep 1, 2020
Status verified date
May, 2026
Completion date
Jul 1, 2026
Anticipated
Primary completion date
Feb 9, 2026
Eligibility Criteria
Sex: All
Age: 8 - 12
Healthy Volunteers: Accepted
Enrollment
214 participants
Anticipated
Allocation
Randomized
Intervention Model
Crossover
Primary purpose
Other
Arms
experimental: Attention Deficit Hyperactivity Disorder (ADHD)
no intervention: Typically developing controls (TDC)
Interventions
Methylphenidate
Placebo
Primary outcome measure
Central contacts
Locations
Kennedy Krieger Institute
Recruiting
Baltimore, Maryland, United States, 21205
Contacts
Cincinnati Children's Hospital Medical Center
Recruiting
Cincinnati, Ohio, United States, 45229
Contacts
Sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Last update posted
May 15, 2026
Last verified
May, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Donald Gilbert, MD, MS, FAAN, FAAP on 2026-05-15.